<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.thyroidresearchjournal.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Thyroid Research - Latest Articles</title>
        <link>http://www.thyroidresearchjournal.com</link>
        <description>The latest research articles published by Thyroid Research</description>
        <dc:date>2012-05-01T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/5/1/3" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/5/1/2" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/5/1/1" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/4/1/17" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/4/1/16" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/4/1/15" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/4/1/14" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/4/1/13" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/4/1/12" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/4/1/11" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/5/1/3">
        <title>Phylogenetic analysis of the human thyroglobulin regions</title>
        <description>Thyroglobulin is a large protein present in all vertebrates. It is synthesized in the thyrocytes and exported to lumen of the thyroid follicle, where its tyrosine residues are iodinated . The iodinated thyroglobulin is reintegrated into the cell and processed (cleaved to free its two extremities) for thyroid hormone synthesis. Thyroglobulin sequence analysis has identified four regions of the molecule: Tg1, Tg2, Tg3 and ChEL. Structural abnormalities and mutations result in different pathological consequences, depending on the thyroglobulin region affected. We carried out a bioinformatic analysis of thyroglobulin, determining the origin and the function of each region. Our results suggest that the Tg1 region acts as a binding protein on the apical membrane, the Tg2 region is involved in protein adhesion and the Tg3 region is involved in determining the three-dimensional structure of the protein. The ChEL domain is involved in thyroglobulin transport, dimerization and adhesion. The presence of repetitive domains in the Tg1, Tg2 and Tg3 regions suggests that these domains may have arisen through duplication.</description>
        <link>http://www.thyroidresearchjournal.com/content/5/1/3</link>
                <dc:creator>Abdelaziz Belkadi</dc:creator>
                <dc:creator>Caroline Jacques</dc:creator>
                <dc:creator>Frédérique Savagner</dc:creator>
                <dc:creator>Yves Malthièry</dc:creator>
                <dc:source>Thyroid Research 2012, null:3</dc:source>
        <dc:date>2012-05-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-5-3</dc:identifier>
                                <prism:require>/content/figures/1756-6614-5-3-toc.gif</prism:require>
                <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2012-05-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/5/1/2">
        <title>Riedel&apos;s thyroiditis - a case report with genes&apos; expression studies</title>
        <description>Background:
Genetic background of Riedel&apos;s thyroiditis remains unknown. Herein, we describe our results of studies on genes expression levels in Riedel&apos;s thyroiditis.Case report and genetic findingsWe report the case of 48-year old woman with Riedel&apos;s thyroiditis who has presented unusual course of disease with non-specific cervical discomfort, though as with no pain and/or no compression symptoms. After surgery, thyroid specimens were quantitatively evaluated, regarding PIK3CA, PIK3CD, PIK3CG, Tg, TGFB1, THRB, COL1, CDKN1C, CDH3 and CACNA2D2 genes expression levels, by real-time PCR in the ABI PRISM&#174; 7500 Sequence Detection System. Out of 10 above genes, in 2 cases the expression was higher than in respective Controls of unchanged thyroid tissue. In the remaining 8 cases, expression in question became comparable or lower as in Controls.DiscussionThe association between increased expression levels of PIK3CA and CDH3 genes and Riedel&apos;s thyroiditis is not well-defined. However, the increased expression of PIK3CA and CDH3 genes in our case report and in previous studies of other authors on various malignancies may suggest possible molecular relation between Riedel&apos;s thyroiditis and certain neoplastic processes, the relation of which requires further genetic evaluation. It is to be stressed that gene expression studies in Riedel&apos;s thyroiditis are difficult to perform, mainly due to fibrosis, resulting in scarce thyroid specimens and - in consequence - small amount of genetic material.</description>
        <link>http://www.thyroidresearchjournal.com/content/5/1/2</link>
                <dc:creator>Katarzyna Wojciechowska-Durczynska</dc:creator>
                <dc:creator>Adam Durczynski</dc:creator>
                <dc:creator>Stanislaw Sporny</dc:creator>
                <dc:creator>Janusz Strzelczyk</dc:creator>
                <dc:creator>Andrzej Lewinski</dc:creator>
                <dc:source>Thyroid Research 2012, null:2</dc:source>
        <dc:date>2012-03-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-5-2</dc:identifier>
                                <prism:require>/content/figures/1756-6614-5-2-toc.gif</prism:require>
                <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2012-03-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/5/1/1">
        <title>Gender-specific regulation of response to thyroid hormone in aging.</title>
        <description>Background:
Similar to other systems, the endocrine system is affected by aging. Thyroid hormone, the action of which is affected by many factors, has been shown to be associated with longevity. The most useful marker for the assessment of thyroid hormone action is TSH level. Although age and gender are believed to modify the pituitary set point or response to free thyroid hormone concentration, the precise age- and gender-dependent responses to thyroid hormone have yet to be reported.
Methods:
We analyzed the results of 3564 thyroid function tests obtained from patients who received medication at both out- and inpatient clinics of Shinshu University Hospital. Subjects were from among those with thyroid function test results in the normal or mildly abnormal range. Based on a log-linear relationship between the concentrations of FHs and TSH, we established the putative resistance index to assess the relation between serum FH and TSH levels.
Results:
Free thyroid hormone and TSH concentration showed an inverse log-linear relation. In males, there was a negative relationship between the free T3 resistance index and age. In females, although there were no relationships between age and FHs, the indices were positively related to age.
Conclusions:
These findings indicated that there is a gender-specific response to thyroid hormone with aging. Although the TSH level is a useful marker for the assessment of peripheral thyroid hormone action, the values should be interpreted carefully, especially with regard to age- and gender-related differences.</description>
        <link>http://www.thyroidresearchjournal.com/content/5/1/1</link>
                <dc:creator>Satoru Suzuki</dc:creator>
                <dc:creator>Shin-ichi Nishio</dc:creator>
                <dc:creator>Teiji Takeda</dc:creator>
                <dc:creator>Mitsuhisa Komatsu</dc:creator>
                <dc:source>Thyroid Research 2012, null:1</dc:source>
        <dc:date>2012-01-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-5-1</dc:identifier>
                                <prism:require>/content/figures/1756-6614-5-1-toc.gif</prism:require>
                <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-01-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/4/1/17">
        <title>Remission of anorexia nervosa after thyroidectomy: A report of two cases with Graves&apos; disease and anorexia nervosa</title>
        <description>We report two patients with anorexia nervosa and Graves&apos; disease who received subtotal thyroidectomy for Graves&apos; disease and concomitantly experienced remission from anorexia nervosa. Both were young women (aged 20 and 26) at the time of surgery. Both had well controlled thyroid function and eating behavior at the time of surgery. Both were followed for over five years without relapse of anorexia nervosa or hyperthyroidism. These cases suggest the existence of an endocrine factor originating from the thyroid gland that is involved in the pathogenesis of anorexia nervosa. Since patients of thyroidectomy can remain in good health with supplement of thyroxine alone, it can be hypothesized that this anorexigenic endocrine factor is an evolutionary relic not necessary for the normal function of humans and does not have physiological effects unless secreted beyond normal levels. Given that, it implies the existence of a creature in the animal kingdom for which such an anorexigenic hormone is essential for survival. Migrating birds eat beyond their caloric expenditure before migration and become anorexic for the duration of their flight. It is also known that their thyroid function is elevated during migration. The normal physiology of migration is a complex mechanism involving the hypothalamic, pituitary, thyroid, adrenal and reproductive hormones. The mechanism of disease, however, can be simpler. A review of the literature is presented that suggest a heretofore unreported thyroid hormone, which is involved in the regulation of migration behavior, may be the responsible factor behind anorexia nervosa.</description>
        <link>http://www.thyroidresearchjournal.com/content/4/1/17</link>
                <dc:creator>Hitoshi Noguchi</dc:creator>
                <dc:creator>Tsukasa Murakami</dc:creator>
                <dc:creator>Shinya Uchino</dc:creator>
                <dc:creator>Hiroto Yamashita</dc:creator>
                <dc:creator>Shiro Noguchi</dc:creator>
                <dc:source>Thyroid Research 2011, null:17</dc:source>
        <dc:date>2011-12-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-4-17</dc:identifier>
                                <prism:require>/content/figures/1756-6614-4-17-toc.gif</prism:require>
                <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2011-12-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/4/1/16">
        <title>Coincidence of remission of postpartum Graves&apos; disease and use of omega-3 fatty acid supplements</title>
        <description>I developed Graves&apos; Disease four months postpartum. After one year on propylthiouracil, I learned that omega-3 fatty acids may reduce inflammation associated with certain autoimmune disorders, although no investigations for thyroiditis have been reported. Within eight weeks of beginning flaxseed oil supplements, TSH levels normalized, but fell somewhat when flaxseed was decreased and PTU discontinued. During another pregnancy, plasma TSH normalized, but was again suppressed by four weeks postpartum, then undetectable by four months. This time, flaxseed supplementation alone coincided with TSH normalization. Omega-3 fatty acids should be investigated as a potential treatment for autoimmune thyroid disease.</description>
        <link>http://www.thyroidresearchjournal.com/content/4/1/16</link>
                <dc:creator>Sarah Breese McCoy</dc:creator>
                <dc:source>Thyroid Research 2011, null:16</dc:source>
        <dc:date>2011-11-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-4-16</dc:identifier>
                                <prism:require>/content/figures/1756-6614-4-16-toc.gif</prism:require>
                <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2011-11-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/4/1/15">
        <title>Aberrant DNA methylation of drug metabolism and transport genes in nodular goiter</title>
        <description>The genes encoding drug-metabolizing enzymes and transporters play an important role in maintaining the normal life processes of human body. Their disorder or defect will lead to the occurrence and development of various diseases. Currently, most of studies have focused on genetic variations in these genes, however, in the present study, we analyzed promoter methylation of 11 drug metabolism and transport genes in a cohort of nodular goiter and normal thyroid tissues using methylation-specific PCR (MSP). Our data first revealed a distinct methylation profiling in drug metabolism and transport genes between nodular goiter and normal thyroid tissues, particularly ABCB4, CYP1B1 and CYP24A1 and SLC1A2. Given these genes contribute to the development and progression of various diseases, such as multidrug resistance and tumorigenesis, these epigenetic events may thus play a critical role in the pathogenesis of nodular goiter.</description>
        <link>http://www.thyroidresearchjournal.com/content/4/1/15</link>
                <dc:creator>Lihong Zhang</dc:creator>
                <dc:creator>Jing Shi</dc:creator>
                <dc:creator>Li Xu</dc:creator>
                <dc:creator>Bingyin Shi</dc:creator>
                <dc:creator>Peng Hou</dc:creator>
                <dc:creator>Meiju Ji</dc:creator>
                <dc:source>Thyroid Research 2011, null:15</dc:source>
        <dc:date>2011-10-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-4-15</dc:identifier>
                                <prism:require>/content/figures/1756-6614-4-15-toc.gif</prism:require>
                <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2011-10-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/4/1/14">
        <title>Assessment of Japanese iodine intake based on seaweed consumption in Japan: A literature-based analysis
</title>
        <description>Japanese iodine intake from edible seaweeds is amongst the highest in the world. Predicting the type and amount of seaweed the Japanese consume is difficult due to day-to-day meal variation and dietary differences between generations and regions. In addition, iodine content varies considerably between seaweed species, with cooking and/or processing having an influence on iodine content. Due to all these factors, researchers frequently overestimate, or underestimate, Japanese iodine intake from seaweeds, which results in misleading and potentially dangerous diet and supplementation recommendations for people aiming to achieve the same health benefits seen by the Japanese. By combining information from dietary records, food surveys, urine iodine analysis (both spot and 24-hour samples) and seaweed iodine content, we estimate that the Japanese iodine intake--largely from seaweeds--averages 1,000-3,000 &#956;g/day (1-3 mg/day).</description>
        <link>http://www.thyroidresearchjournal.com/content/4/1/14</link>
                <dc:creator>Theodore Zava</dc:creator>
                <dc:creator>David Zava</dc:creator>
                <dc:source>Thyroid Research 2011, null:14</dc:source>
        <dc:date>2011-10-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-4-14</dc:identifier>
                                <prism:require>/content/figures/1756-6614-4-14-toc.gif</prism:require>
                <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2011-10-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/4/1/13">
        <title>Cytometric evaluation of intracellular  IFN-gamma AND IL-4 levels in thyroid follicular cells from patients with autoimmune thyroid diseases </title>
        <description>Background:
In recent few years is underlined that altered balance of pro- and anti-inflammatory cytokines play an important role in the pathogenesis of AITD.The aim of this study was to estimate intracellular INF-&#947; and IL-4 levels in thyroid-infiltrating lymphocytes and thyrocytes isolated from thyroid tissues in 54 adolescent patients aged 8-21 years, with Graves&apos; disease (GD; n = 18), Hashimoto&apos;s thyroiditis (HT; n = 18) and non-toxic multinodular goiter (NTMG; n = 18).
Methods:
Fresh thyroid tissues were taken on culture medium RPMI -1640, it was mechanically prepared. In next step were added cell activators -12- myristate 13- the acetate (PMA) and Ionomycin as well as the inhibitor of transportation of proteins - Breferdin A. They were cultured 24 hours in 50 ml flasks at 37&#176;C in a 5-95% CO2-air water-saturated atmosphere. After that, thyrocytes were identified by mouse mAb directed against human TPO epitope 64 conjugated with rabbit anti-mouse antibodies IgG (Fab&apos;)2 labeled by FITC. After incubation at room temperature to each of samples added reagent A fixative the cellular membrane. In next step into the cell suspensions were added reagent B to permeabilization of cellular membrane and specific anti-IL-4-PE or anti-IFN-&#947;-PE mAbs. Identification of intracellular cytokines in T lymphocytes was performed in the same procedure with application of anti-CD4-PerCP and anti-CD8-PerCP mAbs specific for T lymphocytes. The cells were analyzed in a flow cytometry (Coulter EPICS XL).
Results:
In examined group of patients with GD we observed statistically significant higher mean percentage of cells with phenotype CD4+IL-4 (p &lt; 0.05; p &lt; 0.025), CD8+IL-4 (p &lt; 0.033; p &lt; 0.01) and TFCs-IL-4+ (p &lt; 0.05; p &lt; 0.01) in comparison to patients with HT and NTMG. The analysis of mean percentages of positive TILs and TFCs with intracellular INF-g levels in patients with HT revealed statistically significant increase percentage of CD4+INF-&#947; (p &lt; 0.04; p &lt; 0.001), CD8+ INF-&#947; (NS; p &lt; 0.025), TFCs+INF-&#947; (p &lt; 0.03; p &lt; 0.001) cells in comparison to the percentage of positive cells from patients with GD and NTMG.
Conclusions:
We conclude that human thyrocytes in autoimmune thyroid disorders could be a source of cytokine production and that their activation influences local interaction with T lymphocytes inflowing to the thyroid gland.</description>
        <link>http://www.thyroidresearchjournal.com/content/4/1/13</link>
                <dc:creator>Artur Bossowski</dc:creator>
                <dc:creator>Jerzy Harasymczuk</dc:creator>
                <dc:creator>Anna Moniuszko</dc:creator>
                <dc:creator>Anna Bossowska</dc:creator>
                <dc:creator>Maciej Hilczer</dc:creator>
                <dc:creator>Karol Ratomski</dc:creator>
                <dc:source>Thyroid Research 2011, null:13</dc:source>
        <dc:date>2011-09-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-4-13</dc:identifier>
                                <prism:require>/content/figures/1756-6614-4-13-toc.gif</prism:require>
                <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2011-09-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/4/1/12">
        <title>Histological subtype is the most important determinant of survival in metastatic papillary thyroid cancer.</title>
        <description>Background:
Papillary thyroid cancer (PTC) comprises the commonest type of thyroid cancer and carries the highest rate of survival. However, when metastatic disease occurs, survival is significantly affected.
Methods:
We aimed to identify prognostic histopathological and clinical factors that modify survival in metastatic PTC. All cases of metastatic PTC treated at our department in the last 20 years were reviewed and analyzed.
Results:
Histological subtype was the most important determinant of survival, as classic PTC demonstrated clearly improved survival compared to follicular subtype of PTC and other less frequently seen histological subtypes. The instant risk of death for the other histological subtypes was 4.56 times higher than the risk for the classic papillary type. Overall, a 10-year survival of 76.6% in our patients was seen.
Conclusions:
Patients with aggressive variants of PTC are more at risk for the development of metastatic disease. In these patients, established treatment modalities (surgery, radioiodine therapy) should be offered promptly, as well as close follow-up.</description>
        <link>http://www.thyroidresearchjournal.com/content/4/1/12</link>
                <dc:creator>Alexandra Chrisoulidou</dc:creator>
                <dc:creator>Maria Boudina</dc:creator>
                <dc:creator>Athanasios Tzemailas</dc:creator>
                <dc:creator>Eleni Doumala</dc:creator>
                <dc:creator>Paschalia Iliadou</dc:creator>
                <dc:creator>Frideriki Patakiouta</dc:creator>
                <dc:creator>Kalliopi Pazaitou-Panayiotou</dc:creator>
                <dc:source>Thyroid Research 2011, null:12</dc:source>
        <dc:date>2011-07-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-4-12</dc:identifier>
                                <prism:require>/content/figures/1756-6614-4-12-toc.gif</prism:require>
                <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2011-07-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/4/1/11">
        <title>Validity of multiplex biomarker model of 6 genes for the differential diagnosis of thyroid nodules </title>
        <description>Background:
Currently the cytological examination of fine needle aspiration (FNA) biopsies is the standard technique for the pre-operative differential diagnosis of thyroid nodules. However, the results may be non-informative in ~20% of cases due to an inadequate sampling and the lack of highly specific, measurable cytological criteria, therefore ancillary biomarkers that could aid in these cases are clearly needed. The aim of our study was to evaluate the mRNA expression levels of 8 candidate marker genes as the diagnostic biomarkers for the discrimination of benign and malignant thyroid nodules and to find a combination of biomarkers with the highest diagnostic value.Materials and methodsmRNA expression levels of eight candidate marker genes - BIRC5, CCND1, CDH1, CITED1, DPP4, LGALS3, MET and TFF3 was measured by real-time RT-PCR in paired nodular and surrounding normal thyroid tissue specimens of 105 consecutive patients undergoing thyroid surgery and compared between different types of thyroid lesions.
Results:
Significant differences in the mRNA expression levels between the normal and malignant thyroid tissues and between benign and malignant nodules were found for BIRC5, CCND1, CITED1, DPP4, LGALS3, MET and TFF3, but not CDH1. On a single gene basis, relative quantity (RQ) of LGALS3 had the highest diagnostic value for the discrimination of malignant and benign thyroid nodules (AUC = 0.832, P &lt; 0.0001 and 90.9% sensitivity and 65.6% specificity at the optimal cut-off on ROC curve). The only two-marker set that outperformed LGALS3 was RQ sum of LGALS3 and BIRC5 (AUC = 0.841, P &lt; 0.0001). An application of multivariate logistic regression analysis resulted in the generation of a multiplex biomarker model based on LGALS3, BIRC5, TFF3, CCND1, MET and CITED1 that had considerably higher specificity than a single marker or two marker gene-based models (AUC = 0.895, P &lt; 0.0001, 70.5% sensitivity and 93.4% specificity).
Conclusions:
This study confirmed that mRNA expression levels of 7 out of 8 candidate genes analysed have a diagnostic value for the distinction of benign and malignant thyroid nodules. The multiplex biomarker model based on 6 genes outperformed a single marker or two marker-based models and warrants feasibility studies on FNA biopsies and the validation in a larger cohort of patients.</description>
        <link>http://www.thyroidresearchjournal.com/content/4/1/11</link>
                <dc:creator>Kristine Ducena</dc:creator>
                <dc:creator>Arturs Abols</dc:creator>
                <dc:creator>Janis Vilmanis</dc:creator>
                <dc:creator>Zenons Narbuts</dc:creator>
                <dc:creator>Juris Tars</dc:creator>
                <dc:creator>Diana Andrejeva</dc:creator>
                <dc:creator>Aija Line</dc:creator>
                <dc:creator>Valdis Pirags</dc:creator>
                <dc:source>Thyroid Research 2011, null:11</dc:source>
        <dc:date>2011-06-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-4-11</dc:identifier>
                                <prism:require>/content/figures/1756-6614-4-11-toc.gif</prism:require>
                <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2011-06-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

